CITOKINE RELEASE SYNDROME MANAGEMENT IN ADULTS AND PEDIATRIC PATIENTS
DOI:
https://doi.org/10.46765/2675-374X.2022v3n2p163Keywords:
cytokine release syndrome. CRS. CAR T complications. Anti IL 6. Tocilizumab. Toxicity.Abstract
Chimeric Antigen Receptor (CAR) T cell therapy has demonstrated efficacy in B cell malignances. However, the treatment is not harmless and, in some patients, can lead to a fatal endpoint. For this reason, the knowledge and the early recognition and management of the side effects related to CAR-T cell therapy for the multidisciplinary team is essential. In this article, we have summarized the current recommendations for identification, gradation and management of cytokine release syndrome related to CAR-T cell therapy.
Downloads
Published
11/23/2022
How to Cite
Garcia, J. L., & Rodrigues Kerbauy, F. . (2022). CITOKINE RELEASE SYNDROME MANAGEMENT IN ADULTS AND PEDIATRIC PATIENTS. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 3(2), 163. https://doi.org/10.46765/2675-374X.2022v3n2p163
Issue
Section
Original article
License
Copyright (c) 2022 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
